Octreotide Acetate Injection Recalled for Glass Particle Contamination
Viatris Inc is recalling Octreotide Acetate Injection due to glass particles found in syringes. Approximately 22,400 syringes of lot #AJ21002 (expiration 03/2024) were distributed nationwide.
What this means for you
Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.
Our severity reasoning: This is an FDA Class I recall, the highest classification for drug recalls. FDA Class I is explicitly listed in the Score 5 (Critical) criteria. Glass particle contamination in an injectable drug poses a direct hazard of injection site injury or internal harm if administered.
Plain-English summary
Viatris Inc is recalling Octreotide Acetate Injection 500 mcg/mL in single-dose unit-of-use syringes due to the presence of glass particles in a syringe. The affected lot is #AJ21002 with an expiration date of March 2024. Approximately 22,400 syringes were distributed nationwide in the United States.
The recall was initiated based on a product complaint reporting glass particles in a syringe. Glass particles in an injectable product pose a risk of injection site injury or other harm if the product is administered to a patient.
This prescription medication is intended for subcutaneous or intravenous injection. The affected lot was distributed nationwide and may have reached healthcare facilities, hospitals, pharmacies, and other healthcare settings.
If you have this product, do not use it. Healthcare providers and patients who received this product should contact their pharmacy or healthcare provider. Return any affected product to your pharmacy or the manufacturer.
The recalled product
- Product
- OCTREOTIDE ACETATE (OCTREOTIDE ACETATE)
- Brand
- OCTREOTIDE ACETATE
- Manufacturer
- Viatris Inc
- Category
- Drug — Injectable
- Hazard
- glass-particles
- injection-injury
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AJ21002
- Exp. 03/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · OCTREOTIDE ACETATE
- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin 500 mg Tablets Recalled for Impurity Above Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModerateFentanyl Citrate Sterile Injection Recalled for Subpotent Drug Content
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27